Company Overview: Inovio

Industry News

21 Mar

George Bickerstaff Elected to Inovio’s Board of Directors

PLYMOUTH MEETING, Pa., March 21, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) announced today the election of George Bickerstaff to its Board of Directors. Mr. Bickerstaff is an internationally recognized expert in finance, healthcare and information technology.  He has served Novartis Pharma AG as its chief financial officer...

Read more

13 Feb

Inovio and ApolloBio to Collaborate on Development and Commercialization of HPV Pre-cancer Immunotherapy VGX-3100 in Greater China

PLYMOUTH MEETING, Pa., Feb. 13, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today announced that it has entered into a collaboration and license agreement providing ApolloBio Corporation (NEEQ:430187) with the exclusive right to develop and commercialize VGX-3100, Inovio’s DNA immunotherapy product designed to treat pre-cancers caused by human...

Read more

30 Jan

Inovio Pharmaceuticals to Participate in Upcoming Investment Conferences

PLYMOUTH MEETING, Pa., Jan. 30, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today announced that the Company will participate in the following upcoming investment conferences: BIO CEO & Investor Conference Fireside chat Dr. J. Joseph Kim, President & CEO 10:00AM ET, February 13, 2017 The Waldorf Astoria, New...

Read more

21 Dec

Inovio’s Zika Vaccine Generates Robust Immune Responses in First Human Study

PLYMOUTH MEETING, Pa., Dec. 21, 2016 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today announced its DNA-based Zika vaccine (GLS-5700) generated robust antigen-specific antibody responses in a first-in-man, multi-center phase I trial. In initial testing, Zika-naïve subjects in both low dose and high dose vaccine groups demonstrated Zika antigen-specific...

Read more

1 Dec

Inovio Pharmaceuticals Awarded $6.1 Million Sub-grant Through Wistar Institute to Develop DNA-based Monoclonal Antibodies Against Zika Virus

PLYMOUTH MEETING, Pa. & PHILADELPHIA, Dec. 01, 2016 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) announced today that it has been awarded a $6.1 million sub-grant through The Wistar Institute to develop a DNA-based monoclonal antibody designed to provide a fast-acting treatment against Zika infection and its debilitating effects....

Read more

Page 1 of 1012345...10...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address